BioNTech · conference-presentation
BioNTech | Investor Day Presentation Deck | 156 slides
120 pages · 4 arc beats · 2 loops
BioNTech | Investor Day Presentation Deck | 156 slides
BioNTech · 2022-06 arc beats above · slides in the middle · loops below · scroll → 2 LOOPS
15101520253035404550556065707580859095100105110115120
Deck intelligence map
4 coverage by narrative range · generated from this deck JSON
Narrative range 55 total
Metadata
Components
Metrics
Tools
Frameworks
Beats
Loops
Problem Statement 3 slides 100% 3/3 slides 100% 3/3 slides · 15 hits — 0/3 slides
— 0/3 slides
— 0/3 slides
100% 3/3 slides 100% 3/3 slides Solution Overview 11 slides 100% 11/11 slides 100% 11/11 slides · 45 hits — 0/11 slides
18.2% 2/11 slides 54.5% 6/11 slides 100% 11/11 slides 100% 11/11 slides · 22 hits Market Opportunity 11 slides 100% 11/11 slides 100% 11/11 slides · 56 hits — 0/11 slides
45.5% 5/11 slides · 6 hits 9.1% 1/11 slides 100% 11/11 slides — 0/11 slides
Product Pipeline 30 slides 100% 30/30 slides 100% 30/30 slides · 143 hits — 0/30 slides
23.3% 7/30 slides · 8 hits 36.7% 11/30 slides 100% 30/30 slides — 0/30 slides
Slide inventory
120 every slide · same image gating as the playbook
01
The year '2022' is stylized with biological imagery inside the digits.front_matter
07
The slide uses a central human body diagram surrounded by cell types and lists of functions and diseases to illustrate the systemic importance of the immune sysframe_problem
09
Includes a list of key metrics and a bottom banner highlighting broader societal impact.summarize
10
The timeline uses a split-level design to accommodate many events over a long period.establish_context
12
Uses a horizontal progression layout to represent strategic evolution.plan_implementation
14
The slide uses a hexagonal chain diagram to represent the five pillars. Icons at the top right correspond to the five pillars.present_framework
15
The slide uses a side-by-side comparison to establish the biological foundation of the company's platform.establish_context
16
The slide maps biological interactions (APC, T cell, Tumor cells, etc.) to five specific therapeutic modalities (mRNA vaccines, cell therapies, immunomodulatorspresent_framework
17
The slide uses a hexagonal process flow to represent the five pillars.present_framework
18
The slide uses a process diagram to illustrate the evolution of cancer cells from healthy cells.diagnose_problem
19
The slide outlines a two-stage process: Mutation discovery (sequencing, analysis, identification, validation) followed by Immunogenicity testing (peptide immuniillustrate_case
20
The slide uses a biological process diagram on the left and a scatter plot of mutation burden across cancer types on the right.present_framework
21
The slide highlights the first step of a five-step process, with visual illustrations of blood draw and tissue/sample transport.present_solution
Open slide detailLoop · Golden Circle
22
The slide highlights step 2 (Mapping of mutations) and provides a visual representation of DNA sequencing comparing normal and cancer cells.plan_implementation
Open slide detailLoop · Golden Circle
23
The slide highlights the transition from automated computational prediction to human expert verification.present_framework
Open slide detailLoop · Golden Circle
24
The slide highlights the manufacturing process for personalized cancer vaccines, specifically focusing on the mRNA backbone and neoantigen integration.present_solution
Open slide detailLoop · Golden Circle
25
Source: Lang F, et al. Nature Rev Drug Discov 2022; 21:261-282.analyze_data
Open slide detailLoop · Golden Circle
26
The chart uses a broken y-axis to show high-frequency outliers alongside the long tail of low-frequency targets.analyze_data
Open slide detailLoop · Golden Circle
27
The slide uses a horizontal sequence of hexagonal icons to represent the pillars. The third pillar is highlighted in green, while the others are faded.present_framework
Open slide detailLoop · Golden Circle
28
The slide uses a hub-and-spoke diagram centered on the BioNTech logo to illustrate the diversity of their technology platforms.present_framework
Open slide detailLoop · Golden Circle
29
The slide uses a modular diagram to show how different mRNA types (uRNA, modRNA, saRNA, taRNA) are combined with delivery vehicles (LPX, LNP, Polyplexes) to tarpresent_framework
Open slide detailLoop · Golden Circle
30
The slide uses a structured table format to map technical mRNA variations to clinical outcomes.present_framework
Open slide detailLoop · Golden Circle
31
The slide uses a combination of microscopy images and a line chart to demonstrate efficacy.analyze_data
32
The slide uses a combination of molecular biology diagrams and experimental data (flow cytometry and VNT-titer scatter plots) to support the efficacy of taRNA.present_solution
33
The slide uses a matrix-like table to show the application of different mRNA technologies across a portfolio of infectious disease programs.present_framework
34
Includes schematic of lipid bilayer structure, RNA-lipoplex screening process, and bioluminescence imaging data.present_solution
35
Includes chemical structure of PSAR-LNP components and a line chart comparing in vivo expression profiles.present_solution
36
The slide uses a horizontal chain of hexagons to represent the pillars. The fourth pillar is highlighted in a darker green, indicating it is the subject of the present_framework
38
The slide uses a 5-step process diagram to illustrate the workflow, with a specific focus on step 3 (Neoantigen prediction) being powered by AI/ML.present_solution
39
The slide uses biological diagrams to illustrate the process of T-cell recognition and tumor cell interaction, alongside a list of key criteria for neoantigen ppresent_framework
40
The slide uses a funnel to represent the reduction of candidates from exome variations to validated immunogenic neo-epitopes.present_framework
41
The slide illustrates the methodology for ranking neoantigens, likely for personalized cancer vaccine development.analyze_data
42
The ROC curve shows the new model (blue) consistently outperforming the baseline NetMHCpan 4.1 EL (orange).present_solution
43
The slide illustrates a multi-stage computational pipeline (Structural modeling -> EWS score -> ML modeling) and compares detection timing against WHO designatipresent_solution
44
The slide shows structural models of spike proteins (Wuhan, Beta, Omicron) alongside scatter plots correlating epitope alteration/semantic change/immune escape analyze_data
45
The chart displays genetic mutations (columns) against specific viral lineages (rows). Colors indicate mutation status (common vs. not common) and potentially oanalyze_data
46
The slide uses a horizontal hexagonal chain to represent the five pillars.present_framework
48
Hub-and-spoke diagram layout showing central infrastructure and four peripheral capability areas.present_framework
49
The slide uses a map-based visualization to communicate operational scale and geographic reach.other
50
The slide uses two timeline-style metrics to show growth in clinical batch capacity and bulk mRNA batch size.quantify_opportunity
51
The slide highlights the rapid conversion of a Novartis facility into a high-capacity mRNA vaccine production site.illustrate_case
52
The slide uses a before-after framework to highlight operational efficiency gains.present_solution
53
The slide highlights two specific facilities (Germany and US) and lists 8 key benefits of automation.present_solution
54
Uses a before-after framing to contrast the abstract challenge with the concrete physical solution.propose_solution
56
The slide uses a chain of five hexagons to represent the pillars, with icons corresponding to each.present_framework
57
The slide uses a hub-and-spoke style layout with icons representing each pillar.present_framework
58
The slide uses a honeycomb/hexagonal tiling layout to represent the interconnected nature of their R&D platforms.present_framework
61
The slide uses a three-column layout to present the problem, with a footer section listing the company's solutions.diagnose_problem
Open slide detailBeat · Market Opportunity
65
The slide uses a before-after framing to contrast efficacy and safety data.present_solution
Open slide detailBeat · Market Opportunity
66
The slide uses a timeline-like progression of vaccine development stages.present_solution
Open slide detailBeat · Market Opportunity
67
The table highlights that all tested Omicron-modified vaccines met the superiority criterion (lower bound of 95% CI for GMR > 1.0).analyze_data
Open slide detailBeat · Market Opportunity
68
The table highlights that all tested Omicron-modified vaccines met the super superiority criterion (GMR lower bound > 1.5).analyze_data
Open slide detailBeat · Market Opportunity
69
The table highlights the seroresponse difference and non-inferiority status for participants without prior infection.analyze_data
Open slide detailBeat · Market Opportunity
70
The chart compares baseline (Prevax 1MPD) vs post-vaccination GMTs for various BNT162b2 and Bivalent formulations.analyze_data
Open slide detailBeat · Market Opportunity
73
The chart illustrates the need for faster vaccine development cycles due to the rapid turnover of viral strains.propose_solution
74
The slide uses a circular phylogenetic tree to illustrate the dominance of the Omicron clade (GRA) in recent outbreak sequences.analyze_data
75
The chart uses a highlighted box to focus on the Omicron period starting December 2021.analyze_data
76
Includes a 3D structural model of the RBD with color-coded mutation sites and a corresponding table of amino acid changes.analyze_data
77
Data shows neutralization titers for OMI and Bivalent vaccines against BA.1 and BA.4/5 variants.analyze_data
79
The chart shows that the Omi BA.4/5 and b2 + Omi BA.4/5 vaccines maintain higher neutralization ratios against Omicron sub-lineages compared to the original BNTanalyze_data
81
The diagram uses a hub-and-spoke model centered on 'PREPAREDNESS' feeding into 'Response'.present_solution
83
The slide uses a map-based visual to illustrate a hub-and-spoke network model for vaccine manufacturing.present_solution
84
The slide uses a three-column layout to frame the problem and the proposed solution.diagnose_problem
86
The slide uses a structural biology diagram to explain the modularity of endolysins.present_framework
87
Shows log-scale reduction in CFU/ml for pathogens vs no significant impact on beneficial bacteria.analyze_data
91
The slide features a portrait of Özlem Türeci, co-founder and Chief Medical Officer of BioNTech.transition
Open slide detailBeat · Product Pipeline
92
The slide maps biological interactions (APC, T cell, Tumor cells) to numbered therapeutic interventions.present_framework
Open slide detailBeat · Product Pipeline
93
The slide uses a Gantt-style visualization for clinical trial phases.plan_implementation
Open slide detailBeat · Product Pipeline
94
The slide uses a process-flow style to show how different modalities combine to produce specific clinical outcomes.present_solution
Open slide detailBeat · Product Pipeline
95
The slide features a stylized, microscopic-style illustration of a molecular structure.front_matter
Open slide detailBeat · Product Pipeline
96
The slide uses a biological process diagram to explain the mechanism of action and a branching logic diagram to explain the product portfolio strategy.present_solution
Open slide detailBeat · Product Pipeline
97
The slide uses a circular process flow for the 5 steps and a feedback loop for the continuous platform evolution.plan_implementation
Open slide detailBeat · Product Pipeline
98
Includes process flow, flow cytometry data, and scatter plot of TCR frequency.summarize
Open slide detailBeat · Product Pipeline
99
The slide uses a comparison table to contrast early-line vs late-line settings across three key biological dimensions.compare_peers
Open slide detailBeat · Product Pipeline
100
Clinical trial design diagram showing patient flow, randomization, and treatment arms.present_framework
Open slide detailBeat · Product Pipeline
101
The slide uses a process flow diagram to illustrate the current patient journey and outcomes.diagnose_problem
Open slide detailBeat · Product Pipeline
102
The slide uses a process flow diagram to illustrate the clinical trial patient journey from screening to randomization and treatment arms.present_framework
Open slide detailBeat · Product Pipeline
103
The slide uses a timeline diagram to show the treatment protocol and lists to summarize clinical context.illustrate_case
Open slide detailBeat · Product Pipeline
104
Includes a pie chart of responder status and a line chart showing T-cell expansion over time, plus a summary table of median T-cell percentages.analyze_data
Open slide detailBeat · Product Pipeline
105
Shows stacked bar chart of neoantigen immunogenicity and a line chart of IFNy spots over time for responders.analyze_data
Open slide detailBeat · Product Pipeline
106
Kaplan-Meier plot showing significant difference in RFS between responders and non-responders.analyze_data
Open slide detailBeat · Product Pipeline
107
The slide illustrates the modular nature of the FixVac platform, showing how different antigen cassettes are used for specific cancers (Melanoma, HPV16+ HNSCC, present_solution
Open slide detailBeat · Product Pipeline
108
The slide uses a combination of metrics and a callout box to frame the clinical problem.diagnose_problem
Open slide detailBeat · Product Pipeline
109
Includes a citation to a Nature article and specific trial results (Lipo-MERIT).analyze_data
Open slide detailBeat · Product Pipeline
110
The chart is a 'spider plot' or 'spaghetti plot' tracking individual patient lesion kinetics.analyze_data
Open slide detailBeat · Product Pipeline
111
The chart displays individual patient responses, categorized by treatment type and dose, with markers for partial response (PR) and stable disease (SD/irSD).analyze_data
Open slide detailBeat · Product Pipeline
112
The slide uses a swimmer plot to visualize disease-free survival and stacked bar charts for T-cell response rates.analyze_data
Open slide detailBeat · Product Pipeline
113
The slide uses a process flow diagram to illustrate the trial design.illustrate_case
Open slide detailBeat · Product Pipeline
114
The table categorizes candidates by platform, indication, and current clinical milestone status.plan_implementation
Open slide detailBeat · Product Pipeline
116
Includes binding affinity data and a biological mechanism diagram.present_solution
Open slide detailBeat · Product Pipeline
117
The slide uses a process flow diagram to illustrate the transition from Phase 1 to Phase 2a.plan_implementation
Open slide detailBeat · Product Pipeline
118
Data cut-off: August 31, 2020. MTD not reached.analyze_data
Open slide detailBeat · Product Pipeline
119
Waterfall plot displays individual patient responses categorized by cancer type and prior PD-(L)1 treatment status.analyze_data
Open slide detailBeat · Product Pipeline
120
Includes clinical trial data for BNT311; displays best change from baseline and longitudinal change over study weeks.analyze_data
Open slide detailBeat · Product Pipeline